ARA 290 (Cibinetid) · DOSSIER

ARA 290 (Cibinetid)

ARA 290 · Cibinetide · Peptide · 11 AS
LEGAL DE · NOT APPROVEDEVIDENCE · EARLY CLINICAL STUDIES2 STUDIES
FIG.01 — SIGNAL CHAIN
02

Mechanism of action

What ARA 290 (Cibinetid) does in the body — step by step.

01

ARA 290 (cibinetide) is a short peptide derived from helix B of erythropoietin (EPO).

02

It binds to the so-called innate repair receptor (a complex of the EPO receptor and the β-common receptor subunit) without having the erythropoietic (blood-forming) action of EPO.

03

Tissue-protective and inflammation-modulating effects have been described.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
ARA 290 has been investigated in early clinical studies, particularly in sarcoidosis-associated small-fibre neuropathy.
ARA 290 has been investigated in early clinical studies, particularly in sarcoidosis-associated small-fibre neuropathy.
Studies describe an improvement of neuropathic symptoms and an increase in corneal nerve fibres.
The studies are mostly small and exploratory; there is no market approval.
The substance has received orphan-drug status for certain indications.
04

Known risks

Without human data, safety statements are limited. What is known:

01
Safety profile only from small, exploratory studies
02
Injection-site reactions possible
03
Long-term safety not established
04
Product quality cannot be verified from unapproved sources
05

Cited studies

Chronological — links lead to the source.

2013
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss
PubMed 24136731 →
2017
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss
PubMed 28475703 →
06

Frequently asked questions

What is ARA 290 (Cibinetid)?+

ARA 290 (cibinetide) is a short peptide derived from helix B of erythropoietin (EPO).

What type of peptide is ARA 290 (Cibinetid)?+

ARA 290 (Cibinetid) belongs to the Other class.

What is ARA 290 (Cibinetid) used for?+

In research, ARA 290 (Cibinetid) has primarily been investigated in the context of: Recovery, Immunomodulation. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.

Is ARA 290 (Cibinetid) legal in Germany?+

ARA 290 (Cibinetid) is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is ARA 290 (Cibinetid) FDA-approved / legal in the US?+

No. ARA 290 (Cibinetid) is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is ARA 290 (Cibinetid) legal in Canada?+

No. ARA 290 (Cibinetid) is not authorized by Health Canada and not intended for human consumption.

Where can I buy ARA 290 (Cibinetid)?+

Peptica sells nothing and names no sources. ARA 290 (Cibinetid) is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of ARA 290 (Cibinetid)?+

Peptica publishes no dosing. There are no approved dosing guidelines for ARA 290 (Cibinetid); figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is ARA 290 (Cibinetid) banned in sport (WADA)?+

ARA 290 (Cibinetid) is currently not on the WADA Prohibited List.

What are the known risks of ARA 290 (Cibinetid)?+

Documented risks include: Safety profile only from small, exploratory studies; Injection-site reactions possible. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is ARA 290 (Cibinetid)?+

The evidence is classified as “early clinical studies”. 2 studies are cited on this page.

What is the molecular weight of ARA 290 (Cibinetid)?+

ARA 290 (Cibinetid) has a molar mass of about 1257.3 Da.

Which peptides are related to ARA 290 (Cibinetid)?+

Closely related entries: Erythropoetin (EPO). A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

ARA 290 (cibinetide) is not approved as a medicine; it is in clinical development. As it has no erythropoietic action, it is not in the same category as EPO; it is not WADA-listed. Obtaining it as a research chemical carries quality and safety risks.

Legal status varies by country and can change. This is not legal advice.

SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01